Idera Enters Agreement with NCI to Evaluate Use of TLR Antagonists for Treatment of Genetically Defined Lymphomas

Idera Pharmaceuticals, Inc.

today announced that it has entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the National Cancer Institute (NCI) to evaluate the Company's Toll-like receptor (TLR) antagonists as a potential approach to the treatment of certain genetically defined B-cell lymphomas. "We are pleased to have entered into this agreement, and we look forward to communicating further on it as the work underway proceeds," said Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera Pharmaceuticals. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals technology platform involves creating novel synthetic RNA- and DNA-based compounds to modulate immune responses.